top of page
Search


FDA Meeting Package Requirements: What Submission Teams Need to Know
FDA’s August 2026 final guidance clarifies the submission requirements and timelines that inform when cross-functional development teams and their regulatory submission partners should begin developing and publishing formal meeting packages.
Aug 315 min read


How to Outsource Regulatory Submission Management
A Practical Guide for Early-Stage Pharma and Biotech For small and early-stage pharmaceutical and biotechnology companies approaching their first IND or scaling toward a major filing, outsourcing regulatory submission management can be an important part of the strategy. This guide walks you through exactly how to do it. Outsourcing Regulatory Submission Management as an Operational Strategy There’s a common assumption in early-stage pharma and biotech that outsourcing is what
Jun 258 min read


The Critical Relationship Between Regulatory Affairs and Regulatory Operations
Understanding what Regulatory Affairs and Regulatory Operations teams do, and how they work together, is one of the most practical things a sponsor can do to protect submission quality and timelines.
May 146 min read


eCTD Granularity Best Practices: How to Structure Your FDA Submission Files
One of the most common questions we hear from teams preparing their first eCTD submission is: "How should we divide our content into separate files?" The answer has significant implications for reviewer experience, amendment efficiency, and long-term submission management.
Apr 155 min read


Working with the FDA Reviewer in Mind: Why Reviewer-Friendly Submissions Matter
When most teams think about their investigational or marketing submission, they focus on compliance: Does it pass validation? Are all required documents included? Is the structure correct? These are critical questions, but they are not the only ones that matter. A more important question for consideration: Can an FDA reviewer easily find what they need, understand your data, and make a confident decision about your application? This shift in perspective from "technically comp
Feb 245 min read


The Hidden Costs of Building a Regulatory Publishing Function
When smaller pharma and biotech organizations reach the point of regulatory submission planning, there’s often a pivotal decision to make: do we build an internal publishing capability or outsource? On paper, growing the team internally seems logical, especially if there is a steady pipeline, experienced regulatory leads, or a desire to maintain direct control. In-house publishing can make sense when organizations have high submission volume, a stable pipeline, and a dedicat
Jan 265 min read


Understanding the IND: The Critical Milestone Between Discovery and Development
An IND submission is the culmination of years of discovery, experimentation, and refinement; the point where hundreds of data points, experiments, and insights are distilled into a single, coherent story for the FDA.
Oct 13, 20256 min read


Understanding FDA File Format Requirements: A Critical Step in Submission Readiness
This blog explores the file formats accepted by the FDA, the common pitfalls of working with non-PDF documents, and best practices for ensuring your submission is compliant, efficient, and fully reviewable.
Jun 23, 20256 min read


The Importance of Effective Communication When Working on Marketing Application Submissions
Managing, compiling, and creating a marketing application in the pharmaceutical, biotech, and medical device industries is a complex,...
Apr 30, 20254 min read


Addressing Common Bottlenecks in Marketing Applications
By Allison Steffen The submission of a marketing application, whether a New Drug Application (NDA) or a Biologics License Application...
Apr 2, 20253 min read


Reflections on the 2025 DIA RSIDM Conference: Progress, Collaboration, and the Future of Regulatory Submissions
By Allison Steffen The DIA Regulatory Submissions, Information, and Document Management (RSIDM) Conference was held in February again...
Mar 4, 20253 min read


Why Early-Stage Biotech and Pharma Teams Should Outsource Regulatory Publishing
For small and resource-constrained teams, outsourcing regulatory submission publishing can offer significant advantages.
Nov 21, 20244 min read


The Complexity of eCTD Compliance: Common Challenges and Practical Solutions
The Electronic Common Technical Document (eCTD) has become the global standard for submitting regulatory information to agencies.
Oct 2, 20244 min read


The FDA's Orange Book
Thr Orange Book provides a comprehensive list of FDA-approved drug products and their therapeutic equivalence evaluations.
Aug 28, 20244 min read


What are the Clinical Components of the eCTD?
A detailed discussion of the clinical components in Modules 2 and 5 of the eCTD submission
Jul 23, 20244 min read


What’s Included in the Nonclinical Portions of the eCTD?
This blog post will outline the structure and purpose of the nonclinical components of the eCTD.
Jun 26, 20245 min read


The ICH Process for Developing Guidelines
Ever wonder how those harmonized guidelines that address the technical and scientific aspects of drug development come about? The...
May 14, 20243 min read


Reflections from the 2024 DIA RSIDM Conference
Allison Steffen The recent DIA Regulatory Submissions, Information, and Document Management (RSIDM) Conference offered many practical...
Mar 19, 20243 min read


What are the Quality (CMC) Components of the eCTD?
Module 3, dedicated to Quality (Chemistry, Manufacturing, and Controls), is an important yet complex component of the eCTD.
Mar 1, 20245 min read


What We Can Expect with the FDA’s ESG NextGen Project
The FDA ESG NextGen will be scalable, secure, more user-friendly, and designed to handle the full spectrum of electronic submissions.
Dec 11, 20233 min read
"WAYS OF WORKING" BLOG
bottom of page
